MedTrace Logo

Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)

NCT05138523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2021-12-01

No results posted yet for this study

Summary

A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)

Conditions

  • Chronic Hepatitis c

Interventions

COMBINATION_PRODUCT

Sofosdac®

Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir

Sponsors & Collaborators

  • Pharmaceutical Research Unit, Jordan

    collaborator OTHER

  • Beker Laboratories

    lead INDUSTRY

Principal Investigators

  • Nabil Debzi, MD; Professor · CHU Mustapha Hepatology department

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-21
Primary Completion
2020-11-18
Completion
2021-06-22

Countries

  • Algeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138523 on ClinicalTrials.gov